SCHEMBL4925243

SCHEMBL4925243

COc1ccc(CNC(=O)c2cc3cc(Cl)ccc3o2)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 1/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TP53 P04637 5/20 0.53
MAPT P10636 3/20 0.53
HDAC3 O15379 3/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC2 Q92769 3/20 0.52
LMNA P02545 1/20 0.52
TAS1R3 Q7RTX0 5/20 0.51
TAS1R1 Q7RTX1 5/20 0.51
HDAC4 P56524 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925034 0.89 HDAC3 (0.54) KMT2ATP53HDAC3HDAC1HDAC2
SCHEMBL4917286 0.86 TP53 (0.67) SMN1; SMN2MEN1TSHRMAPK1HTT
SCHEMBL4927036 0.85 HDAC3 (0.64) MEN1HTTKMT2ATP53MAPT
SCHEMBL4927279 0.83 HDAC3 (0.58) SMN1; SMN2HTTKMT2AHSD17B10TP53
SCHEMBL4929507 0.81 HDAC3 (0.47) SMN1; SMN2MEN1TSHRMAPK1HTT
SCHEMBL14270762 0.81 TP53 (0.73) SMN1; SMN2MEN1TSHRKMT2ANPSR1
SCHEMBL4928789 0.81 KDM4E (0.56) SMN1; SMN2MEN1TSHRHTTKMT2A
SCHEMBL4926057 0.79 NPC1 (0.58) SMN1; SMN2MEN1TSHRKMT2ANPSR1
SCHEMBL4920599 0.79 HDAC3 (0.61) SMN1; SMN2MEN1KMT2ATP53HDAC3
SCHEMBL4926117 0.77 KDM4E (0.59) SMN1; SMN2MEN1TSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US claimed
EP-1838690-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY Devgen N.V. (BE) 2007-10-03 EP claimed
WO-2006066879-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY DEVGEN N.V. (BE) 2006-06-29 WO claimed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity KCNA4, HCN4, KCNN4 SMN1; SMN2 1993/4885MEN1 2435/4885TSHR 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.